Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05058651
Title Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Metastatic Small Cell Neuroendocrine Carcinomas That Originate Outside the Lung
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

neuroendocrine carcinoma


Atezolizumab + Carboplatin + Etoposide

Atezolizumab + Cisplatin + Etoposide

Cisplatin + Etoposide

Carboplatin + Etoposide

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.